CAR-T Drugmaker Poseida Snags $142 Million in Financing Led by Novartis

In January, San Diego-based Poseida Therapeutics eyed a potential $115 million initial public offering to support the development of its CAR-T medicines to treat various blood and solid tumors. The company seems to have scrapped that and instead raised $142 million, with significant support from Novartis.